Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $54.3 million versus the consensus estimate of $51.45 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $198-202 million, versus the consensus of $193.4 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13